The Russian side has signed several contracts with Indian firms to manufacture over 700 million doses of the anti-coronavirus Sputnik V vaccine, Russian Foreign Minister Sergey Lavrov said on Tuesday and indicated that there was also a possibility that an Indian vaccine could be manufactured in Russia.
At a joint press event after holding wide-ranging talks with External Affairs Minister S Jaishankar, Lavrov lauded India's vaccine manufacturing capacity and said Russia has close cooperation with the country on vaccines to combat the coronavirus pandemic.
He said the Russian Direct Investment Fund (RDIF) signed contracts with several Indian contractors to manufacture the Sputnik V vaccine to the tune of 700-750 million doses.
This becomes possible because of the manufacturing capacity in India, he added.
"I do not exclude (the scenario) that further cooperation could cover the manufacturing of the Indian vaccine in Russia. I guess the experts are supposed to discuss this and to assess the efficiency of such a cooperation," Lavrov said while answering a question on the possibility of India's indigenous vaccine COVAXIN being manufactured in Russia in the near future.
In his remarks at the press interaction, Jaishankar said in meeting the COVID challenge, the India-Russia pharmaceutical collaboration has become more serious and "we have a Russian vaccine under discussion for production in India".
Responding to the question on Sputnik V, he said, "We had a discussion and clearly that decision has to be taken by our regulatory authorities."
"For us, were those vaccines to be made in India, it would be one more affirmation of the importance of made in India and our own vaccine capacities," he asserted.
Jaishankar said that so far India has sent COVAXIN to three-four countries abroad and going forward it would certainly like to promote "made in India and invented in India".
The RDIF and drug firm Panacea Biotec on Monday said they have agreed to produce 100 million doses per year of Sputnik V COVID-19 vaccine in India.
The RDIF has also partnered with other Indian pharma firms such as Hetero, Gland Pharma and Stelis Biopharma to produce millions of Sputnik V vaccine in India.
An expert panel of India's central drug authority has also sought additional data and information from Dr Reddy's Laboratories, which has sought emergency use authorisation for Sputnik V, while deferring its decision on it till the next meeting, according to sources.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU